RxDoctor Payments Data

Adriane Marchese, MD

Family Medicine · Farmington Hills, MINPI 1265952543

Payments from drug & device makers

$2,150in general payments, 2019–2025

Across 46 payments — averaging $46.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$557
  • Dexcom, Inc.$490
  • Lilly USA, LLC$311
  • AstraZeneca$245
  • AbbVie$231
  • Boehringer Ingelheim$122
  • plus $194 from 9 others

What the payments were for

  • Food & beverage$2,150100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,150 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$21,331
Medicare patients
63
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$57,033
RexultiBrexpiprazole20$45,253
WegovySemaglutide21$40,432
MounjaroTirzepatide23$31,792
RybelsusSemaglutide21$23,849
FarxigaDapagliflozin Propanediol31$23,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$22,355
Xigduo XrDapaglifloz Propaned/Metformin17$18,047
XareltoRivaroxaban12$17,086
JardianceEmpagliflozin23$14,613
Duloxetine Hcl51$4,488
Atorvastatin Calcium148$1,907
Levothyroxine Sodium135$1,510
Celecoxib52$1,082
Rosuvastatin Calcium50$992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$557$121,31572 claims
Lilly USA, LLCMounjaro$311$31,79223 claims
AstraZenecaFarxiga$245$23,48231 claims
GSKTrelegy Ellipta$22$22,35528 claims
Johnson & JohnsonXarelto$20$17,08612 claims
Boehringer IngelheimJardiance$122$14,61323 claims
AbbVieSynthroid$231$53211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →